BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8445676)

  • 1. Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15.
    Beckwith M; Urba WJ; Longo DL
    J Natl Cancer Inst; 1993 Mar; 85(6):483-8. PubMed ID: 8445676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antineoplastic dolastatins: potent inhibitors of hematopoietic progenitor cells.
    Jacobsen SE; Ruscetti FW; Longo DL; Keller JR
    J Natl Cancer Inst; 1991 Nov; 83(22):1672-7. PubMed ID: 1749020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay.
    Aherne GW; Hardcastle A; Valenti M; Bryant A; Rogers P; Pettit GR; Srirangam JK; Kelland LR
    Cancer Chemother Pharmacol; 1996; 38(3):225-32. PubMed ID: 8646796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines.
    Ali MA; Rosati R; Pettit GR; Kalemkerian GP
    Anticancer Res; 1998; 18(2A):1021-6. PubMed ID: 9615758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dolastatin 10 and dolastatin 15: effects of two natural peptides on growth and differentiation of leukemia cells.
    Steube KG; Grunicke D; Pietsch T; Gignac SM; Pettit GR; Drexler HG
    Leukemia; 1992 Oct; 6(10):1048-53. PubMed ID: 1405759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules.
    Bai R; Friedman SJ; Pettit GR; Hamel E
    Biochem Pharmacol; 1992 Jun; 43(12):2637-45. PubMed ID: 1632820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dolastatins, a family of promising antineoplastic agents.
    Poncet J
    Curr Pharm Des; 1999 Mar; 5(3):139-62. PubMed ID: 10066887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
    Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
    Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dolastatins on human B-lymphocytic leukemia cell lines.
    Hu ZB; Gignac SM; Quentmeier H; Pettit GR; Drexler HG
    Leuk Res; 1993 Apr; 17(4):333-9. PubMed ID: 8487581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A natural peptide, dolastatin 15, induces G2/M cell cycle arrest and apoptosis of human multiple myeloma cells.
    Sato M; Sagawa M; Nakazato T; Ikeda Y; Kizaki M
    Int J Oncol; 2007 Jun; 30(6):1453-9. PubMed ID: 17487366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10.
    Bai RL; Pettit GR; Hamel E
    Biochem Pharmacol; 1990 Oct; 40(8):1859-64. PubMed ID: 2242019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines.
    Maki A; Mohammad R; Raza S; Saleh M; Govindaraju KD; Pettit GR; al-Katib A
    Anticancer Drugs; 1996 May; 7(3):344-50. PubMed ID: 8792010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15.
    Poncet J; Busquet M; Roux F; Pierré A; Atassi G; Jouin P
    J Med Chem; 1998 Apr; 41(9):1524-30. PubMed ID: 9554885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.
    Bai R; Pettit GR; Hamel E
    Biochem Pharmacol; 1990 Jun; 39(12):1941-9. PubMed ID: 2353935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma.
    Maki A; Diwakaran H; Redman B; al-Asfar S; Pettit GR; Mohammad RM; al-Katib A
    Anticancer Drugs; 1995 Jun; 6(3):392-7. PubMed ID: 7670136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc.
    Turner T; Jackson WH; Pettit GR; Wells A; Kraft AS
    Prostate; 1998 Feb; 34(3):175-81. PubMed ID: 9492845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification.
    Kalemkerian GP; Ou X; Adil MR; Rosati R; Khoulani MM; Madan SK; Pettit GR
    Cancer Chemother Pharmacol; 1999; 43(6):507-15. PubMed ID: 10321512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of Dolastatin 15 mimetic peptoids.
    Schmitt J; Bernd M; Kutscher B; Kessler H
    Bioorg Med Chem Lett; 1998 Feb; 8(4):385-8. PubMed ID: 9871690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the antimitotic natural product dolastatin 10, and related peptides, on the human malarial parasite Plasmodium falciparum.
    Fennell BJ; Carolan S; Pettit GR; Bell A
    J Antimicrob Chemother; 2003 Apr; 51(4):833-41. PubMed ID: 12654761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity.
    Verdier-Pinard P; Kepler JA; Pettit GR; Hamel E
    Mol Pharmacol; 2000 Jan; 57(1):180-7. PubMed ID: 10617693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.